Laboratorios Farmaceuticos Rovi (ROVI) AI Stock Analysis

• Market Cap: €2.67B
• Dividend Yield: 1.69%
• Average Volume (3M): 104.51K
• Price to Earnings (P/E): 19.4
• Beta (1Y): 0.46
• Revenue Growth: -1.49%
• EPS Growth: 4.04%
• Country: ES
• Employees: 2,197
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): 0.35
• Shares Outstanding: 51,235,764
• 10 Day Avg. Volume: 76,319
• 30 Day Avg. Volume: 104,506
• PEG Ratio: 0.50
• Price to Book (P/B): 4.71
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 35.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €77.75
• Price Target Upside: 47.39% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

Laboratorios Farmaceuticos Rovi exhibits a strong financial base with robust profitability and a stable balance sheet, despite facing recent revenue challenges. The technical analysis indicates short-term positive momentum, though long-term resistance persists. Valuation and earnings call analyses suggest moderate investment appeal, with future growth potential balanced by current operational difficulties.

Laboratorios Farmaceuticos Rovi Business Overview & Revenue Model

Company Description

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and Medicebrán to treat attention deficit hyperactivity disorder in children and teenagers. The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT Exprès that are contrast injection systems and compatible disposable material. It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves wholesalers, doctors, nursing staff, pharmacists, and patients. It has a collaboration with Moderna, Inc. for manufacturing mRNA COVID-19 vaccine candidate. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.

How the Company Makes Money

ROVI generates revenue through multiple streams, primarily from the sale of its proprietary pharmaceutical products and from offering contract manufacturing services to other pharmaceutical companies. The company's proprietary products include a range of specialty pharmaceuticals, with a significant portion of revenue derived from its low molecular weight heparins, such as Bemiparin. Additionally, ROVI acts as a contract development and manufacturing organization (CDMO), providing services that include drug formulation, manufacturing, and packaging for third-party clients. Strategic partnerships, such as licensing agreements and collaborations with other pharmaceutical companies, also play a crucial role in ROVI's revenue model, allowing the company to expand its market reach and product offerings.

Laboratorios Farmaceuticos Rovi Financial Statement Overview

Summary

Laboratorios Farmaceuticos Rovi shows a solid financial foundation with strong profitability and a stable balance sheet. While recent revenue growth has been challenging, the company maintains operational efficiency and financial stability. Continued focus on cash flow management will be key to sustaining growth and supporting strategic initiatives.

Income Statement

Laboratorios Farmaceuticos Rovi exhibits strong profitability metrics with a consistent high gross profit margin and net profit margin over the years. However, recent revenue growth has slowed, with a slight decline in the most recent year. EBIT and EBITDA margins remain robust, indicating operational efficiency despite the revenue dip.

Balance Sheet

The company maintains a healthy balance sheet with a favorable debt-to-equity ratio, indicating prudent leverage levels. The return on equity remains strong, reflecting efficient use of shareholder funds. Equity ratio shows stability, underscoring financial resilience in the industry.

Cash Flow

Operating cash flow is strong, supporting net income effectively, though free cash flow growth has been inconsistent. The company has demonstrated capability in generating free cash flow but should focus on sustaining and improving cash flow generation to support future growth.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
763.75M	829.51M	817.70M	648.68M	419.96M
	Gross Profit
478.35M	483.34M	519.61M	384.82M	241.31M
	EBIT
179.54M	220.25M	255.85M	181.57M	74.68M
	EBITDA
207.69M	245.81M	281.49M	204.72M	93.28M
	Net Income Common Stockholders
136.88M	170.34M	199.67M	153.08M	61.06M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
27.41M	25.32M	124.94M	99.03M	53.16M
	Total Assets
832.02M	799.88M	878.70M	732.68M	574.44M
	Total Debt
114.41M	65.43M	72.14M	73.14M	73.52M
	Net Debt
87.22M	40.10M	-52.81M	-25.89M	20.36M
	Total Liabilities
250.48M	256.39M	357.32M	261.70M	200.74M
	Stockholders Equity
572.03M	539.39M	520.01M	470.98M	373.70M
Cash Flow		Free Cash Flow
76.06M	58.06M	186.21M	108.50M	7.18M
	Operating Cash Flow
138.28M	113.25M	237.60M	149.44M	46.88M
	Investing Cash Flow
-81.06M	-52.03M	-57.15M	-40.84M	-39.63M
	Financing Cash Flow
-55.36M	-160.84M	-154.54M	-62.73M	-21.52M

Laboratorios Farmaceuticos Rovi Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 52.75
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:ROVI, the sentiment is Positive. The current price of 52.75 is above the 20-day moving average (MA) of 50.50, above the 50-day MA of 51.51, and below the 200-day MA of 64.65, indicating a neutral trend. The MACD of 0.33 indicates Negative momentum. The RSI at 59.12 is Neutral, neither overbought nor oversold. The STOCH value of 58.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:ROVI.

Laboratorios Farmaceuticos Rovi Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ROVI	71 Outperform	€2.67B	19.35	25.24%	1.69%	-1.49%	4.04%
Sector *	52 Neutral	$5.15B	3.56	-42.52%	2.83%	14.56%	-0.50%

Laboratorios Farmaceuticos Rovi Corporate Events

ROVI Secures €36.3 Million for Innovative Drug Development Project

Laboratorios Farmacéuticos ROVI, S.A. has been granted a subsidy of 36.3 million euros from the Center for Technological Development and Innovation (CDTI) for its R&D project, LAISOLID, under the IPCEI Med4Cure initiative. This funding will support the development of new aseptic filling technologies and methodologies to accelerate drug development, with potential applications in tissue regeneration and long-acting injectable formulations, enhancing ROVI’s position in cutting-edge health solutions.

ROVI Announces Upcoming Shareholders’ Meeting and Dividend Proposal

Laboratorios Farmacéuticos ROVI has announced the call for its Ordinary General Shareholders’ Meeting scheduled for June 18, 2025. The meeting will address several key issues, including the proposal to distribute a dividend of 0.9351 euros per share for the 2024 financial year. This announcement reflects ROVI’s commitment to maintaining transparency and engaging with its shareholders, potentially impacting its financial outlook and investor relations.

ROVI Reports First-Quarter 2025 Liquidity Operations

ROVI announced its first-quarter 2025 operations under a liquidity contract with Bestinver SV, S.A., revealing a purchase of 260,242 shares and sale of 256,242 shares, resulting in a final balance of 10,000 shares. The operations reflect a strategic approach to managing liquidity and share value, potentially impacting investor confidence and market positioning.

ROVI Unveils Strategic Update for Next Growth Phase

Laboratorios Farmacéuticos ROVI, S.A. has announced an update to its strategic plans, which will be shared during a Capital Markets Day event with analysts and investors. This update is part of ROVI’s efforts to create value for investors as it enters its next phase of growth, potentially impacting its market positioning and stakeholder interests.

ROVI Unveils Strategic Update for Growth Phase

Laboratorios Farmacéuticos ROVI, S.A. has announced an update to its strategy, which will be presented during a meeting with analysts and investors. This strategic update is part of ROVI’s efforts to create value for investors as it enters its next phase of growth.

ROVI Approves 2024 Financial Accounts and Dividend Proposal

ROVI’s Board of Directors has approved the preparation of the company’s annual and consolidated financial accounts for the fiscal year ending December 31, 2024. They have also proposed a dividend distribution of 0.9351 euros per share, representing about 35% of the consolidated net profit. Additionally, the company has approved the publication of several key reports for 2024, including the Annual Financial Report, Corporate Governance Report, and Directors’ Remuneration Report, which will be accessible on their corporate website.

Laboratorios Farmacéuticos Rovi Unveils New Director Remuneration Policy

Laboratorios Farmacéuticos Rovi, S.A. has announced a new remuneration policy for its directors for the years 2025 to 2027, emphasizing principles such as moderation, alignment with market practices, and proportionality. The policy aims to attract and retain directors by aligning their remuneration with long-term company interests, promoting non-discrimination, and ensuring transparency and simplicity in corporate governance, which could enhance stakeholder confidence and support the company’s strategic objectives.